menu

Medical Management of Uterine Fibroids and Endometriosis: The Emerging Value Proposition Surrounding the New Oral GnRH Antagonis

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Medical Management of Uterine Fibroids and Endometriosis: The Emerging Value Proposition Surrounding the New Oral GnRH Antagonists

0.25 credits
15 minutes
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    By 50 years of age, 70% to 80% of women are affected by uterine fibroids, and nearly 10% of women are affected by endometriosis. Clinical trial data demonstrate that GnRH antagonist therapy can dramatically impact pain and bleeding and improve results across all EHP-30 domains. Join Drs. Lee Shulman and Andrea Lukes as they dive into these data and offer strategies to help you better incorporate patient-centric medical management for uterine fibroids and endometriosis into your clinical practice.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Lee Philip Shulman, MD, FACOG, FACMG

    The Anna Ross Lapham Professor and Chief
    Division of Clinical Genetics
    Feinberg School of Medicine of Northwestern University
    Chicago, IL

    Consulting Fees: Agile, Aspira, Bayer, Biogix, Celula China, Daiichi Sankyo, Mayne, Organon, Shield
    Other: Astellas (DSMB Chair)

    Faculty:
    Andrea S. Lukes, MD, MHSc, FACOG
    Founder and CEO
    Carolina Women’s Research and Wellness Center
    Durham, NC 

    Contracted Research:  AbbVie, Bayer, Merck, Myla, Myovant Sciences
    Consulting Fees: Myovant Sciences

    Reviewers/Content Planners/Authors:

    • Barry A. Fiedel, PhD, has nothing to disclose.
    • Kate Nagele has nothing to disclose.
    • Robert Schneider, MSW, has nothing to disclose.
    • Jay Runyon has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify misconceptions and knowledge gaps that clinicians may hold regarding the new oral GnRH antagonist therapies for managing uterine fibroids and/or endometriosis, including an improved understanding of their benefits and disadvantages
    • Differentiate the patient-centric advantages of the new oral GnRH antagonist therapies within the full panoply of interventional choices when managing uterine fibroids or endometriosis
  • Target Audience

    This activity is designed to meet the educational needs of ob-gyns, primary care physicians, family practitioners, nurse practitioners, physician assistants, nurse midwives, emergency department physicians, and other providers who treat and manage patients who may have uterine fibroids and/or endometriosis.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 15 minutes of nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Omnia Education is the leading provider of education for women’s health professionals. Our activities are recognized nationwide for providing credible, relevant, and practical information on issues impacting the female patient. Additionally, our unique focus has transformed the CME learning environment, and our ability to help learners recognize and overcome barriers to optimal performance and optimal patient outcomes has positioned us as a leader in women’s health education.

  • Commercial Support

    This activity is supported by independent educational grants from Pfizer and Myovant Sciences.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    By 50 years of age, 70% to 80% of women are affected by uterine fibroids, and nearly 10% of women are affected by endometriosis. Clinical trial data demonstrate that GnRH antagonist therapy can dramatically impact pain and bleeding and improve results across all EHP-30 domains. Join Drs. Lee Shulman and Andrea Lukes as they dive into these data and offer strategies to help you better incorporate patient-centric medical management for uterine fibroids and endometriosis into your clinical practice.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Lee Philip Shulman, MD, FACOG, FACMG

    The Anna Ross Lapham Professor and Chief
    Division of Clinical Genetics
    Feinberg School of Medicine of Northwestern University
    Chicago, IL

    Consulting Fees: Agile, Aspira, Bayer, Biogix, Celula China, Daiichi Sankyo, Mayne, Organon, Shield
    Other: Astellas (DSMB Chair)

    Faculty:
    Andrea S. Lukes, MD, MHSc, FACOG
    Founder and CEO
    Carolina Women’s Research and Wellness Center
    Durham, NC 

    Contracted Research:  AbbVie, Bayer, Merck, Myla, Myovant Sciences
    Consulting Fees: Myovant Sciences

    Reviewers/Content Planners/Authors:

    • Barry A. Fiedel, PhD, has nothing to disclose.
    • Kate Nagele has nothing to disclose.
    • Robert Schneider, MSW, has nothing to disclose.
    • Jay Runyon has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify misconceptions and knowledge gaps that clinicians may hold regarding the new oral GnRH antagonist therapies for managing uterine fibroids and/or endometriosis, including an improved understanding of their benefits and disadvantages
    • Differentiate the patient-centric advantages of the new oral GnRH antagonist therapies within the full panoply of interventional choices when managing uterine fibroids or endometriosis
  • Target Audience

    This activity is designed to meet the educational needs of ob-gyns, primary care physicians, family practitioners, nurse practitioners, physician assistants, nurse midwives, emergency department physicians, and other providers who treat and manage patients who may have uterine fibroids and/or endometriosis.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 15 minutes of nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Omnia Education is the leading provider of education for women’s health professionals. Our activities are recognized nationwide for providing credible, relevant, and practical information on issues impacting the female patient. Additionally, our unique focus has transformed the CME learning environment, and our ability to help learners recognize and overcome barriers to optimal performance and optimal patient outcomes has positioned us as a leader in women’s health education.

  • Commercial Support

    This activity is supported by independent educational grants from Pfizer and Myovant Sciences.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule15 Aug 2022
Webpack App